BR Biopharma (NASDAQ:BRBI) Releases Quarterly Earnings Results

BR Biopharma (NASDAQ:BRBI) released its earnings results on Thursday. The company reported $0.09 earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $25.13 million during the quarter.

BR Biopharma Stock Down 6.5%

BRBI stock traded down $0.74 during midday trading on Friday, reaching $10.69. 302 shares of the company’s stock traded hands, compared to its average volume of 165. BR Biopharma has a fifty-two week low of $10.90 and a fifty-two week high of $67.01. The stock’s 50-day simple moving average is $11.66.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded BR Biopharma from a “sell (e)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Hedge Funds Weigh In On BR Biopharma

An institutional investor recently bought a new stake in BR Biopharma stock. Acuitas Investments LLC purchased a new position in shares of BR Biopharma, Inc. (NASDAQ:BRBI) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 3,000 shares of the company’s stock, valued at approximately $45,000. BR Biopharma accounts for approximately 3.2% of Acuitas Investments LLC’s investment portfolio, making the stock its 7th largest position.

About BR Biopharma

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.